235:-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups. Previously as a diversified firm, Atlas had raised over $ 3.0 billion of investor commitments across nine venture capital funds. The firm raised $ 705 million for its 2000-vintage fifth fund, $ 600 million for its 2001-vintage sixth fund, $ 385 million for its 2006-vintage seventh fund, $ 283 million for its 2009-vintage eighth fund, and $ 265 million for its 2013-vintage ninth fund. At its largest, the firm held European offices in London, Paris and Munich, and a West Coast office based in
1346:
1336:
1316:
1296:
1286:
1326:
1306:
192:. Atlas' current portfolio comprises biotech companies including Accent Therapeutics, Aerovate Therapeutics, Affinia Therapeutics, Akero Therapeutics, Arkuda Therapeutics, AVROBIO, Be Biopharma, Chroma Medicine, Day One Biopharmaceuticals, Disc Medicine, Dyne Therapeutics, Generation Bio, HotSpot Therapeutics, Ikena Oncology,
246:
In 2015 Atlas raised its first biotech-dedicated fund, Fund X, at $ 280 million. In 2017, Atlas
Venture announced it had raised Fund XI at $ 350 million in capital to invest in early stage biotech companies in the U.S. and around the world. In January 2019, Atlas Venture announced its Opportunity
196:, Kinaset Therapeutics, Korro Bio, Kymera Therapeutics, Mariana Oncology, Matchpoint Therapeutics, Nimbus Therapeutics, Pheon Therapeutics, Obsidian Therapeutics, Q32 Bio, Rectify Pharmaceuticals, Remix Therapeutics, Replimune, Scorpion Therapeutics, Sionna Tehrapeutics,
27:
164:, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $ 450 million in March 2022, after raising its Opportunity Fund II totaling $ 300 million in September 2021.
1216:
794:
208:, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, Cadent Therapeutics, Disarm Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia,
1390:
424:
1289:
1385:
1380:
172:
Atlas has invested in over 150 life sciences startups since it began investing in the sector in 1990. Atlas invests in a range of therapeutic areas and modalities, including
1375:
787:
200:; Third Harmonic Bio, Triana Biomedicines, Versanis Bio, Vigil Neuroscience, and Xilio Therapeutics. Notable prior exits from Atlas’ life sciences portfolio include
502:
571:
863:
637:
629:
1370:
1349:
780:
761:
1261:
335:
409:
477:
421:
322:
1083:
1078:
528:
986:
564:
871:
848:
642:
614:
1319:
1061:
756:
1329:
1299:
751:
557:
1309:
1066:
464:
896:
891:
886:
881:
876:
657:
652:
647:
440:
943:
1153:
1103:
1041:
1001:
948:
708:
683:
392:
1339:
1256:
1251:
240:
161:
73:
216:, Nimbus Apollo, Novexel, Padlock Therapeutics, Rodin Therapeutics, Stromedix, Translate Bio, and U3 Pharma.
1236:
1231:
1186:
205:
111:
938:
1246:
1211:
1108:
713:
228:
1163:
1071:
738:
452:
310:
193:
26:
549:
247:
Fund I raised $ 250 million. In June 2020, Atlas
Venture announced its Fund XII raised $ 400 million.
1191:
976:
853:
104:
1266:
1128:
1036:
1031:
1027:
981:
698:
503:"As market shifts, Atlas Venture closes a $ 250 million fund to support its breakaway biotech bets"
236:
1241:
1201:
1138:
1133:
971:
373:
239:, in addition to the Boston-area headquarters. Today, the firm operates from a single office in
1206:
933:
928:
923:
838:
718:
609:
1046:
915:
826:
619:
1226:
1148:
996:
958:
833:
807:
723:
678:
599:
584:
428:
189:
173:
153:
146:
47:
37:
1051:
966:
843:
803:
673:
604:
580:
1364:
1158:
1143:
1123:
1011:
772:
728:
703:
693:
157:
150:
1271:
1196:
1168:
1113:
1006:
733:
688:
185:
181:
177:
1056:
1221:
991:
478:"Atlas Venture Unveils New $ 350M Fund for Seed Biotech Investments | Xconomy"
1118:
224:
220:
213:
209:
201:
197:
232:
821:
349:
530:
Atlas
Venture Raises $ 400M Fund to Seed Another New Set of Biotechs
410:
Atlas
Venture Closes New Fund with $ 283M, Does the Staffing Shuffle
263:
231:
startup companies. In
October 2014, Atlas announced its shift to a
287:
776:
553:
336:"Atlas Venture Announces $ 300 Million Second Opportunity Fund"
134:
212:, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals,
227:, Atlas historically invested in both life sciences and
1177:
1096:
1020:
957:
914:
905:
862:
814:
666:
628:
592:
130:
120:
110:
100:
80:
69:
61:
53:
43:
33:
1391:Financial services companies established in 1980
323:Atlas Venture Announces $ 450 Million Fund XIII
788:
638:History of private equity and venture capital
565:
374:"Atlas Venture: The Next Chapter - LifeSciVC"
8:
1290:Private equity and venture capital investors
467:. New York Times DealBook, January 20, 2010
465:Atlas Brings Its European Ops Back to Boston
19:
1386:Companies based in Cambridge, Massachusetts
1381:Venture capital firms of the United States
1325:
1305:
1262:Taxation of private equity and hedge funds
1079:Private investment in public equity (PIPE)
911:
795:
781:
773:
572:
558:
550:
18:
1376:Private equity firms of the United States
223:as a subsidiary of NMB Bank, now part of
16:American early-stage venture capital firm
441:Changes in the Atlas Venture partnership
311:Exclusive: Atlas Venture is splitting up
455:. Tech Crunch Europe, January 19, 2010
255:
422:Atlas Venture aims for new $ 500M fund
393:"FKA Atlas Has a New Name: Accomplice"
7:
1371:Dutch companies established in 1980
527:de Crescenzo, Sara (June 5, 2020),
431:. Mass High Tech, November 6, 2008
391:Huang, Gregory T. (June 29, 2015).
453:Atlas Venture ups sticks to Boston
14:
338:(Press release). October 1, 2021.
149:firm that creates and invests in
1345:
1344:
1335:
1334:
1324:
1315:
1314:
1304:
1295:
1294:
1285:
1284:
25:
643:Early history of private equity
264:"Atlas History - Atlas Venture"
1062:Publicly traded private equity
1:
1330:List of venture capital firms
219:Originally formed in 1980 in
1310:List of private equity firms
1067:Business Development Company
288:"Atlas Team - Atlas Venture"
658:Private equity in the 2000s
653:Private equity in the 1990s
648:Private equity in the 1980s
350:"Portfolio - Atlas Venture"
1407:
1154:High-net-worth individuals
944:Leveraged recapitalization
313:. Fortune, October 2, 2014
160:Atlas is headquartered in
1280:
1042:Limited liability company
1002:Venture capital financing
949:Dividend recapitalization
747:
709:High-net-worth individual
684:Corporate venture capital
443:. Fortune, April 8, 2014
24:
412:. XConomy, January 2009
241:Cambridge, Massachusetts
204:, Adnexus Therapeutics,
162:Cambridge, Massachusetts
74:Cambridge, Massachusetts
1109:Institutional investors
206:Alnylam Pharmaceuticals
1247:Liquidation preference
1212:Distribution waterfall
1164:Sovereign wealth funds
714:Institutional investor
229:information technology
1320:Venture capital firms
1072:Venture capital trust
757:Venture capital firms
739:Sovereign wealth fund
194:Intellia Therapeutics
105:venture capital funds
90:Jean-Francois Formela
1300:Private equity firms
1028:Private equity firms
977:Post-money valuation
854:Equity co-investment
752:Private equity firms
135:www.atlasventure.com
1350:Portfolio companies
1267:Undercapitalization
1119:Insurance companies
1037:Limited partnership
982:Pre-money valuation
762:Portfolio companies
593:Investment strategy
237:Seattle, Washington
122:Number of employees
21:
1202:Capital commitment
972:Business incubator
939:Buy–sell agreement
427:2012-10-04 at the
380:. October 2, 2014.
145:is an early-stage
1358:
1357:
1207:Capital structure
1092:
1091:
934:Divisional buyout
929:Management buyout
924:Financial sponsor
770:
769:
719:Insurance company
188:and editing, and
154:startup companies
140:
139:
92:Michael Gladstone
1398:
1348:
1347:
1338:
1337:
1328:
1327:
1318:
1317:
1308:
1307:
1298:
1297:
1288:
1287:
1149:Commercial banks
1139:Investment banks
1047:Carried interest
912:
815:Investment types
797:
790:
783:
774:
620:Leveraged buyout
587:investment firms
574:
567:
560:
551:
542:
541:
540:
538:
524:
518:
517:
515:
514:
509:. 2 January 2019
499:
493:
492:
490:
489:
474:
468:
462:
456:
450:
444:
438:
432:
419:
413:
407:
401:
400:
388:
382:
381:
370:
364:
363:
361:
360:
346:
340:
339:
332:
326:
320:
314:
308:
302:
301:
299:
298:
284:
278:
277:
275:
274:
260:
29:
22:
1406:
1405:
1401:
1400:
1399:
1397:
1396:
1395:
1361:
1360:
1359:
1354:
1340:Angel investors
1276:
1227:High-yield debt
1180:financial terms
1179:
1173:
1088:
1016:
997:Startup company
953:
907:
901:
858:
810:
808:venture capital
801:
771:
766:
743:
724:Investment bank
679:Commercial bank
662:
624:
588:
585:venture capital
578:
547:
545:
536:
534:
526:
525:
521:
512:
510:
501:
500:
496:
487:
485:
476:
475:
471:
463:
459:
451:
447:
439:
435:
429:Wayback Machine
420:
416:
408:
404:
390:
389:
385:
372:
371:
367:
358:
356:
348:
347:
343:
334:
333:
329:
321:
317:
309:
305:
296:
294:
286:
285:
281:
272:
270:
262:
261:
257:
253:
190:anti-infectives
180:/inflammation,
174:immuno-oncology
170:
147:venture capital
123:
95:
93:
91:
89:
87:
86:Kevin Bitterman
83:
65:Michiel de Haan
48:Venture Capital
17:
12:
11:
5:
1404:
1402:
1394:
1393:
1388:
1383:
1378:
1373:
1363:
1362:
1356:
1355:
1353:
1352:
1342:
1332:
1322:
1312:
1302:
1292:
1281:
1278:
1277:
1275:
1274:
1269:
1264:
1259:
1254:
1249:
1244:
1239:
1234:
1229:
1224:
1219:
1214:
1209:
1204:
1199:
1194:
1189:
1183:
1181:
1175:
1174:
1172:
1171:
1166:
1161:
1159:Family offices
1156:
1151:
1146:
1144:Merchant banks
1141:
1136:
1131:
1126:
1121:
1116:
1111:
1106:
1100:
1098:
1094:
1093:
1090:
1089:
1087:
1086:
1081:
1076:
1075:
1074:
1069:
1059:
1054:
1052:Management fee
1049:
1044:
1039:
1034:
1024:
1022:
1018:
1017:
1015:
1014:
1009:
1004:
999:
994:
989:
984:
979:
974:
969:
967:Angel investor
963:
961:
955:
954:
952:
951:
946:
941:
936:
931:
926:
920:
918:
909:
903:
902:
900:
899:
894:
889:
884:
879:
874:
868:
866:
860:
859:
857:
856:
851:
846:
841:
836:
831:
830:
829:
818:
816:
812:
811:
804:Private equity
802:
800:
799:
792:
785:
777:
768:
767:
765:
764:
759:
754:
748:
745:
744:
742:
741:
736:
731:
726:
721:
716:
711:
706:
701:
696:
691:
686:
681:
676:
674:Angel investor
670:
668:
664:
663:
661:
660:
655:
650:
645:
640:
634:
632:
626:
625:
623:
622:
617:
612:
607:
602:
596:
594:
590:
589:
581:Private equity
579:
577:
576:
569:
562:
554:
544:
543:
519:
494:
469:
457:
445:
433:
414:
402:
383:
365:
341:
327:
315:
303:
279:
254:
252:
249:
169:
166:
138:
137:
132:
128:
127:
124:
121:
118:
117:
114:
108:
107:
102:
98:
97:
84:
81:
78:
77:
71:
67:
66:
63:
59:
58:
55:
51:
50:
45:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1403:
1392:
1389:
1387:
1384:
1382:
1379:
1377:
1374:
1372:
1369:
1368:
1366:
1351:
1343:
1341:
1333:
1331:
1323:
1321:
1313:
1311:
1303:
1301:
1293:
1291:
1283:
1282:
1279:
1273:
1270:
1268:
1265:
1263:
1260:
1258:
1255:
1253:
1250:
1248:
1245:
1243:
1240:
1238:
1235:
1233:
1230:
1228:
1225:
1223:
1220:
1218:
1215:
1213:
1210:
1208:
1205:
1203:
1200:
1198:
1195:
1193:
1190:
1188:
1185:
1184:
1182:
1176:
1170:
1167:
1165:
1162:
1160:
1157:
1155:
1152:
1150:
1147:
1145:
1142:
1140:
1137:
1135:
1132:
1130:
1127:
1125:
1124:Fund of funds
1122:
1120:
1117:
1115:
1114:Pension funds
1112:
1110:
1107:
1105:
1102:
1101:
1099:
1095:
1085:
1082:
1080:
1077:
1073:
1070:
1068:
1065:
1064:
1063:
1060:
1058:
1055:
1053:
1050:
1048:
1045:
1043:
1040:
1038:
1035:
1033:
1029:
1026:
1025:
1023:
1019:
1013:
1012:Venture round
1010:
1008:
1005:
1003:
1000:
998:
995:
993:
990:
988:
985:
983:
980:
978:
975:
973:
970:
968:
965:
964:
962:
960:
956:
950:
947:
945:
942:
940:
937:
935:
932:
930:
927:
925:
922:
921:
919:
917:
913:
910:
904:
898:
895:
893:
890:
888:
885:
883:
880:
878:
875:
873:
872:Early history
870:
869:
867:
865:
861:
855:
852:
850:
847:
845:
842:
840:
837:
835:
832:
828:
825:
824:
823:
820:
819:
817:
813:
809:
805:
798:
793:
791:
786:
784:
779:
778:
775:
763:
760:
758:
755:
753:
750:
749:
746:
740:
737:
735:
732:
730:
729:Merchant bank
727:
725:
722:
720:
717:
715:
712:
710:
707:
705:
704:Fund of funds
702:
700:
697:
695:
694:Family office
692:
690:
687:
685:
682:
680:
677:
675:
672:
671:
669:
665:
659:
656:
654:
651:
649:
646:
644:
641:
639:
636:
635:
633:
631:
627:
621:
618:
616:
613:
611:
608:
606:
603:
601:
598:
597:
595:
591:
586:
582:
575:
570:
568:
563:
561:
556:
555:
552:
548:
532:
531:
523:
520:
508:
504:
498:
495:
483:
479:
473:
470:
466:
461:
458:
454:
449:
446:
442:
437:
434:
430:
426:
423:
418:
415:
411:
406:
403:
398:
394:
387:
384:
379:
375:
369:
366:
355:
354:Atlas Venture
351:
345:
342:
337:
331:
328:
324:
319:
316:
312:
307:
304:
293:
292:Atlas Venture
289:
283:
280:
269:
268:Atlas Venture
265:
259:
256:
250:
248:
244:
242:
238:
234:
230:
226:
222:
217:
215:
211:
207:
203:
199:
195:
191:
187:
183:
179:
175:
167:
165:
163:
159:
155:
152:
151:biotechnology
148:
144:
143:Atlas Venture
136:
133:
129:
125:
119:
116:$ 2.2 billion
115:
113:
109:
106:
103:
99:
94:David Grayzel
85:
79:
75:
72:
68:
64:
60:
56:
52:
49:
46:
42:
39:
36:
32:
28:
23:
20:Atlas Venture
1272:Vintage year
1197:Capital call
1169:Crowdfunding
1104:Corporations
1007:Venture debt
734:Pension fund
689:Crowdfunding
546:
535:, retrieved
529:
522:
511:. Retrieved
506:
497:
486:. Retrieved
484:. 2017-06-29
481:
472:
460:
448:
436:
417:
405:
396:
386:
377:
368:
357:. Retrieved
353:
344:
330:
318:
306:
295:. Retrieved
291:
282:
271:. Retrieved
267:
258:
245:
218:
186:cell therapy
182:neuroscience
178:autoimmunity
171:
142:
141:
96:Jason Rhodes
70:Headquarters
34:Company type
1134:Foundations
1057:Pledge fund
849:Secondaries
615:Secondaries
378:Life Sci VC
88:Bruce Booth
1365:Categories
1222:Envy ratio
1129:Endowments
992:Seed money
906:Terms and
513:2019-01-03
507:TechCrunch
488:2017-07-26
359:2016-03-15
297:2016-03-15
273:2017-10-25
251:References
82:Key people
1192:Cap table
1097:Investors
1021:Structure
839:Mezzanine
827:Leveraged
699:Endowment
667:Investors
610:Mezzanine
537:March 17,
533:, Xconomy
225:ING Group
221:Amsterdam
214:MorphoSys
1242:Leverage
1178:Related
908:concepts
425:Archived
210:Exelixis
202:Actelion
198:Synlogic
101:Products
44:Industry
1252:M&A
959:Venture
864:History
834:Venture
630:History
600:Venture
482:Xconomy
397:Xconomy
233:biotech
184:, gene/
168:History
156:in the
131:Website
62:Founder
54:Founded
38:Private
1217:EBITDA
916:Buyout
844:Growth
822:Buyout
605:Growth
76:, U.S.
1032:funds
897:2020s
892:2010s
887:2000s
882:1990s
877:1980s
1084:SPAC
1030:and
987:SAFE
806:and
583:and
539:2021
158:U.S.
57:1980
1257:PME
1237:IRR
1232:IPO
1187:AUM
112:AUM
1367::
505:.
480:.
395:.
376:.
352:.
290:.
266:.
243:.
176:,
126:29
796:e
789:t
782:v
573:e
566:t
559:v
516:.
491:.
399:.
362:.
325:.
300:.
276:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
